JP2005523882A - 高濃度タンパク質製剤および製造の方法 - Google Patents

高濃度タンパク質製剤および製造の方法 Download PDF

Info

Publication number
JP2005523882A
JP2005523882A JP2003535713A JP2003535713A JP2005523882A JP 2005523882 A JP2005523882 A JP 2005523882A JP 2003535713 A JP2003535713 A JP 2003535713A JP 2003535713 A JP2003535713 A JP 2003535713A JP 2005523882 A JP2005523882 A JP 2005523882A
Authority
JP
Japan
Prior art keywords
protein
weight percent
mixture
pharmaceutical composition
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003535713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005523882A5 (cg-RX-API-DMAC7.html
Inventor
エッター、ジェフリー ビー.
シー. サマニエゴ、エイドリアン
エフ. カーペンター、ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RxKinetix Inc
University of Colorado Boulder
Original Assignee
RxKinetix Inc
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RxKinetix Inc, University of Colorado Boulder filed Critical RxKinetix Inc
Publication of JP2005523882A publication Critical patent/JP2005523882A/ja
Publication of JP2005523882A5 publication Critical patent/JP2005523882A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2003535713A 2001-10-16 2002-10-16 高濃度タンパク質製剤および製造の方法 Pending JP2005523882A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33021301P 2001-10-16 2001-10-16
PCT/US2002/032872 WO2003032907A2 (en) 2001-10-16 2002-10-16 High-concentration protein formulations and method of manufacture

Publications (2)

Publication Number Publication Date
JP2005523882A true JP2005523882A (ja) 2005-08-11
JP2005523882A5 JP2005523882A5 (cg-RX-API-DMAC7.html) 2006-01-05

Family

ID=23288780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003535713A Pending JP2005523882A (ja) 2001-10-16 2002-10-16 高濃度タンパク質製剤および製造の方法

Country Status (8)

Country Link
US (1) US8372798B2 (cg-RX-API-DMAC7.html)
EP (1) EP1441748A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005523882A (cg-RX-API-DMAC7.html)
CN (1) CN1604788B (cg-RX-API-DMAC7.html)
AU (1) AU2002335815A1 (cg-RX-API-DMAC7.html)
BR (1) BR0213298A (cg-RX-API-DMAC7.html)
MX (1) MXPA04003640A (cg-RX-API-DMAC7.html)
WO (1) WO2003032907A2 (cg-RX-API-DMAC7.html)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540589A (ja) * 2007-10-01 2010-12-24 アンスティテュ、ナショナル、ド、ラ、サント、エ、ド、ラ、ルシェルシュ、メディカル(アンセルム) ポロキサマー・タンパク質粒子のマイクロカプセル化
JP2015509542A (ja) * 2012-03-07 2015-03-30 アミカス、セラピューティックス、インコーポレイテッドAmicus Therapeutics,Inc. ポンペ病の処置のための高濃度α−グルコシダーゼ組成物
US10208299B2 (en) 2014-09-30 2019-02-19 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10857212B2 (en) 2015-12-30 2020-12-08 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US12246062B2 (en) 2017-05-15 2025-03-11 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US7879320B2 (en) * 2004-05-17 2011-02-01 Ares Trading S.A. Hydrogel interferon formulations
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2021042090A2 (en) * 2020-11-27 2021-03-04 Schott Ag System for long time storage of pharmaceutical compositions at low temperatures

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
JPH09510182A (ja) * 1993-11-17 1997-10-14 エルディーエス・テクノロジーズ・インコーポレーテッド カプセル封入されたドラッグデリバリー用透明液
US5861158A (en) * 1993-11-17 1999-01-19 The United States Of America As Represented By The Deptartment Of Health And Human Services Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5702717A (en) * 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US20050019325A1 (en) * 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
AU2001273034A1 (en) * 2000-06-26 2002-01-08 Rxkinetix, Inc. Composition for delivery of hematopoietic growth factor
US6613907B2 (en) * 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6008064476, MUSTAFA,A.O. et al, "A novel approach for the crystallization of soluble proteins using non−ionic surfactants", Acta Crystallographica, Section D: Biological Crystallography, 1998, Vol.D54, No.1, p.154−158 *
JPN6008064478, "Drug Delivery Matrix Containing Native Protein Precipitates Suspended in a Poloxamer Gel", Journal of Pharmaceutical Sciences, 1997, Vol.86, No.9, p.1006−1010 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540589A (ja) * 2007-10-01 2010-12-24 アンスティテュ、ナショナル、ド、ラ、サント、エ、ド、ラ、ルシェルシュ、メディカル(アンセルム) ポロキサマー・タンパク質粒子のマイクロカプセル化
JP2015509542A (ja) * 2012-03-07 2015-03-30 アミカス、セラピューティックス、インコーポレイテッドAmicus Therapeutics,Inc. ポンペ病の処置のための高濃度α−グルコシダーゼ組成物
JP2018027945A (ja) * 2012-03-07 2018-02-22 アミカス セラピューティックス インコーポレイテッド ポンペ病の処置のための高濃度α−グルコシダーゼ組成物
US10961522B2 (en) 2014-09-30 2021-03-30 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US10208299B2 (en) 2014-09-30 2019-02-19 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US11753632B2 (en) 2014-09-30 2023-09-12 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US11591583B2 (en) 2014-09-30 2023-02-28 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
US11278601B2 (en) 2015-12-30 2022-03-22 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US10857212B2 (en) 2015-12-30 2020-12-08 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US12414985B2 (en) 2015-12-30 2025-09-16 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of Pompe disease
US11441138B2 (en) 2016-03-30 2022-09-13 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US11491211B2 (en) 2016-03-30 2022-11-08 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10512676B2 (en) 2016-03-30 2019-12-24 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US12622952B2 (en) 2016-03-30 2026-05-12 Amicus Therapeutics, Inc. Formulations comprising recombinant acid α-glucosidase
US12686859B2 (en) 2016-03-30 2026-07-21 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
US12246062B2 (en) 2017-05-15 2025-03-11 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase

Also Published As

Publication number Publication date
WO2003032907A3 (en) 2004-02-19
CN1604788B (zh) 2013-04-17
US8372798B2 (en) 2013-02-12
EP1441748A4 (en) 2007-07-11
BR0213298A (pt) 2006-11-07
WO2003032907A2 (en) 2003-04-24
US20030092607A1 (en) 2003-05-15
AU2002335815A1 (en) 2003-04-28
MXPA04003640A (es) 2005-04-11
EP1441748A2 (en) 2004-08-04
CN1604788A (zh) 2005-04-06
WO2003032907A9 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
US8372798B2 (en) High-concentration protein formulations and method of manufacture
JP2000514811A (ja) タンパク質医薬の持続送達のための温度感受性ゲル
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
TWI609697B (zh) 高濃度抗體及蛋白質調配物
JP5941496B2 (ja) 成長ホルモン製剤
CN100352500C (zh) 稳定的抗体液体制剂
AU2010320515B2 (en) Formulations of antibody
JP6444310B2 (ja) モノクローナル抗体の安定化方法
US20080241267A1 (en) Hydrogel Microspheres with Improved Release Profile
CA3129181C (en) Excipient compounds for biopolymer formulations
US10478498B2 (en) Excipient compounds for biopolymer formulations
US20230065872A1 (en) Excipient compounds for protein processing
CA3053909A1 (en) Excipient compounds for protein processing
JP2022551622A (ja) インテグリン抗体の安定な製剤
US20240252596A1 (en) Injectable Polymeric Biopharmaceutical Formulations
TW202304507A (zh) 含有抗muc16x抗cd3雙特異性抗體之穩定調配物
US20200261584A1 (en) Stabilized protein gel preparation
WO2025177156A1 (en) Stable ophthalmic pharmaceutical formulation of aflibercept
US20110223156A1 (en) Reversible gel protein formulation
MXPA99000499A (es) Gel sensible a la temperatura para suministro sostenido de medicamentos con proteinas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051014

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051014

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101015

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110125

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120507